Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

François Ghiringhelli1

  • 1Université de Bourgogne Franche-Comté, 21000 Dijon, France; Centre Georges-François-Leclerc, département d'oncologie médicale, 1, rue du Professeur-Marion, 21000 Dijon, France; Inserm LNC U1231, 21000 Dijon, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy.

Frontiers in oncology·2026
Same author

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026
Same author

IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy.

Journal for immunotherapy of cancer·2026
Same author

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.

Oncoimmunology·2026
Same author

Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The mannosyltransferase DPM1 regulates the activity of ER-stress sensor IRE1 in colorectal cancer.

Nature communications·2026

Immuno-oncology therapies like anti-PD1/PD-L1 antibodies show promise but have limited success. New strategies are exploring patient selection and combination therapies to improve response rates in cancer treatment.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Anti-PD1/PD-L1 antibodies have revolutionized cancer treatment.
  • Monotherapy response rates are limited to 25-30% of patients.
  • Novel strategies are needed to enhance efficacy and predict response.

Purpose of the Study:

  • To review therapeutic strategies for predicting and enhancing response to immuno-oncology therapies.
  • To explore novel approaches in cancer treatment.

Main Methods:

  • Review of current literature on immuno-oncology.
  • Analysis of strategies for patient selection.
  • Evaluation of combination therapies involving checkpoint inhibitors.

Main Results:

  • Limited response rates in current anti-PD1/PD-L1 monotherapy.
Keywords:
BiomarkersBiomarqueursCheckpoint inhibitorsChimio-immunothérapieImmunotherapyImmunothérapie

Related Experiment Videos

  • Development of strategies to improve patient selection.
  • Emerging combination therapies show potential for increased effectiveness.

    • Conclusions:

    • Predictive biomarkers and combination therapies are crucial for improving immuno-oncology outcomes.
    • Further research is needed to validate novel therapeutic associations.